Novartis AG
USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE
Last updated:
Abstract:
The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1.beta. binding antibody or functional fragment thereof.
Status:
Application
Type:
Utility
Filling date:
17 Mar 2021
Issue date:
1 Jul 2021